Cognito collects $73M for light-and-sound Alzheimer's therapy

Mar 22, 2023 · The series B round adds $73 million to Cognito’s coffers, the startup announced Wednesday. It’ll go toward the ongoing pivotal study of the noninvasive headset, which relies …

CouponFollow Extension

$73
OFF

Cognito Collects $73M For Light-and-sound Alzheimer's Therapy

6 days from now

Mar 22, 2023 · The series B round adds $73 million to Cognito’s coffers, the startup announced Wednesday. It’ll go toward the ongoing pivotal study of the noninvasive headset, which relies …

fiercebiotech.com

$73
OFF

Cognito Therapeutics Raises $73M For Non-invasive Neuromod Tech

6 days from now

Mar 22, 2023 · Cognito Therapeutics announced today that it raised $73 million in a Series B financing round to support its neuromodulation technology. Cambridge, Massachusetts–based …

massdevice.com

$73
OFF

Neurotechnology Company Cognito Therapeutics Scores $73M

6 days from now

Mar 23, 2023 · Cognito Therapeutics, a startup using visual and auditory stimulation to treat neurodegenerative disorders, scored $73 million in a Series B funding round led by FoundersX …

mobihealthnews.com

$73
OFF

Cognito Therapeutics Raises $73M Series B To Advance …

6 days from now

Cambridge, MA, March 22, 2023 (Business Wire) -- Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, announced today a …

jacobsmgt.com

$73
OFF

Neurotechnology Company Cognito Therapeutics Scores $73M

6 days from now

Mar 23, 2023 · Cognito Therapeutics, a startup using visual and auditory stimulation to treat neurodegenerative disorders, scored $73 million in a Series B funding round led by FoundersX …

agetech.news

$73
OFF

Cognito Therapeutics Raises $73M In Series B Funding For …

6 days from now

Mar 23, 2023 · Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, has completed a $73M Series B financing round led by …

mpo-mag.com

$73
OFF

Cognito Secures $73m To Advance Neurotechnology Platform For …

6 days from now

Mar 23, 2023 · Cognito Therapeutics has secured $73m in a Series B financing round to support its neuromodulation platform for Alzheimer’s disease. The Massachusetts–based clinical-stage …

nsmedicaldevices.com

$73
OFF

Firm Advises Cognito Therapeutics On $73 Million Series B Financing

6 days from now

Mar 31, 2023 · On March 22, 2023, neurotechnology company Cognito Therapeutics announced a $73 million Series B financing round. The financing was led by FoundersX Ventures with …

wsgr.com

$73
OFF

Neurotechnology Company Cognito Therapeutics Scores $73M

6 days from now

Apr 3, 2023 · Cognito Therapeutics, a Massachusetts-based startup developing a wearable device using visual and auditory stimulation to treat neurodegenerative disorders, has raised …

distilnfo.com

$73
OFF

Cognito Therapeutics Raises $73M Series B To Advance

6 days from now

Mar 22, 2023 · Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, announced today a $73M Series B financing round led by …

financialcontent.com

$73
OFF

Neurotechnology Company Cognito Therapeutics Scores $73M

6 days from now

Mar 27, 2023 · Cognito Therapeutics, a Massachusetts-based startup focused on using noninvasive neuromodulation to treat neurodegenerative diseases, has raised $73 million in a …

distilnfo.com

$73
OFF

Cognito Therapeutics Scores $73m Series B - Venture Capital Journal

6 days from now

Mar 22, 2023 · Cambridge, Massachusetts-based Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, has raised $73 million …

venturecapitaljournal.com

$73
OFF

Series B - Cognito Therapeutics - 2023-03-22 - Crunchbase

6 days from now

Mar 22, 2023 · Business Wire — Cognito Therapeutics Raises $73M Series B to Advance Neurotechnology Platform for Alzheimer’s Disease News • Mar 22, 2023 Fierce Biotech — …

crunchbase.com

$73000000
OFF

Founder Lodge | Cognito Therapeutics, Inc. Raises $73,000,000 At …

6 days from now

Mar 23, 2023 · Cognito Therapeutics, Inc. raises $73,000,000 at Series B on 2023-03-23 in Medical Equipment Manufacturing, industry founded/co-founded by Brent Vaughan ... Series …

founderlodge.com

$35
OFF

Cognito Therapeutics Raises $35M Series B Extension - VatorNews

6 days from now

The round is an extension of the Series B round the company raised $73 million in March 2023 from FoundersX, Morningside, Alzheimer’s Drug Discovery Foundation, IAG Capital, …

vator.tv

FAQs about Cognito collects $73M for light-and-sound Alzheimer's therapy Coupon?

Does Cognito therapeutics have a series B financing?

CAMBRIDGE, Mass.-- ( BUSINESS WIRE )-- Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, announced today a $73M Series B financing round led by FoundersX Ventures with participation from all existing investors. ...

Who is Cognito Therapeutics?

About Cognito Therapeutics Cognito Therapeutics is a clinical-stage neurotechnology company developing disease-modifying therapeutic approaches to treat neurodegenerative disorders. Its non-invasive neuromodulation platform was developed by MIT Professors and scientific founders Li-Huei Tsai and Ed Boyden. ...

Where is Cognito based?

The Company’s lead therapy is currently in a pivotal study in Alzheimer’s Disease and was awarded FDA Breakthrough Device Designation. Cognito is based in Cambridge, MA. For more information, visit www.cognitotx.com. Follow us on Twitter at @cognitotx. ...

Who will join Cognito's Board of directors?

In addition to the financing, Dr. Rick Kuntz, MD, MSc, former Senior Vice President, Chief Medical and Scientific Officer of Medtronic and Helen Liang, Founder & Managing Partner at FoundersX, will join Cognito’s Board of Directors. Dr. ...

Is Cognito a non-invasive neuromodulation device?

Its non-invasive neuromodulation platform was developed by MIT Professors and scientific founders Li-Huei Tsai and Ed Boyden. The Company’s lead therapy is currently in a pivotal study in Alzheimer’s Disease and was awarded FDA Breakthrough Device Designation. Cognito is based in Cambridge, MA. ...

Can a non-drug neuromodulation intervention help treat Alzheimer's & Cognito?

“A non-drug neuromodulation intervention has the potential to better address the complex nature of neurodegenerative diseases such as Alzheimer’s and Cognito is well-positioned to be a leader in this new paradigm,” said Helen Liang, Founder & Managing Partner, FoundersX Ventures. ...